The Philadelphia Eagles will not be penalized by the NFL for their handling of Jalen Hurts' medical situation, as reported by The Athletic. The league determined that the Eagles appropriately managed the process that led to Hurts being cleared to play in Week 5 against the Jacksonville Jaguars in London, despite the discovery of a superficial blood clot in his lungs.

On Monday, the Eagles announced that Hurts is expected to miss the remainder of the 2026 season due to blood clots found in his lungs. The NFL will not impose any sanctions on the franchise for their medical procedures or for failing to designate Hurts with an injury prior to the game.

Last week, the Eagles revealed that a superficial blood clot on Hurts' calf had shown movement, prompting the team to rule him out for their Week 6 game against the Carolina Panthers. This situation raised several questions, especially as it was reported that the NFL had been informed about Hurts' condition.

Key developments included:

• Initial reports indicated the team would not place Hurts on injured reserve.
• Shortly after, Hurts was indeed placed on injured reserve.
• A follow-up scan revealed that Hurts' superficial vein thrombosis had escalated to deep vein thrombosis, involving "bilateral pulmonary emboli."

While there remains confusion regarding why Hurts was allowed to participate in a game and travel internationally with a superficial blood clot, the NFL has concluded that the Eagles acted appropriately in this complex medical situation.